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Abstract. The expression of genes required for progres-
sion through the cell cycle is highly modulated through a
regulatory axis containing the E2F transcription factor
and retinoblastoma tumour suppressor protein families.
One of the genes regulated through this mechanism en-
codes the B-Myb transcription factor, which has been
shown to be critically required for early embryonal de-
velopment in the mouse. Transcriptional activity of B-
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Myb is substantially enhanced in S phase through modi-
fication by cyclin A/cdk2, and the evidence points
squarely to the major role being played by B-Myb during
this phase of the cell cycle. We discuss in this review re-
cent findings suggesting that B-Myb is a multifunctional
protein that has, in addition to its transcriptional proper-
ties, the ability to interact directly with other regulators of
the cell cycle. 
Key words. B-Myb; E2F; p107; cyclin/cdk; phosphorylation; cell cycle; gene repression; transcriptional regulation.
Introduction
The vertebrate Myb transcription factors comprise a
small family of important regulatory proteins. The proto-
typical member, c-Myb, is the cellular progenitor of the
oncogene carried by the AMV and E26 chicken retro-
viruses that transform haematopoietic cells in vivo and in
vitro (reviewed in [1]). Two other members of this family,
A-Myb and B-Myb, were subsequently discovered using
a c-Myb probe to screen human cDNA libraries [2].
These three Myb proteins share a similar domain organi-
sation (see fig. 1 for B-Myb domains). The most con-
served region is the DNA-binding domain located in the
N terminus, which is composed of three imperfect repeats
of 51–52 amino acids that recognise the canonical Myb-
binding site (MBS) C/TAACNG [3, 4]. The central por-
tions of these proteins comprise a less highly conserved
acidic domain which is involved in transcription activa-
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tion and a conserved region (CR) which has variously
been associated with positive and negative effects on
transcriptional activity [5–9]. The C terminus comprises
an autoregulatory domain (negative regulatory domain:
NRD) that suppresses transactivation function [6, 8,
10–14].
The fact that three different Myb proteins have been
found in higher vertebrates suggests that they have spe-
cific and distinct functions. c-Myb is expressed at high
levels in most haematopoietic precursor cells and plays a
crucial role in blood cell development [1, 15, 16]. Indeed,
mice lacking a functional c-myb gene die at day 15 of ges-
tation with multiple defects in fetal liver haematopoiesis
[17]. A-myb is widely expressed in mitotically active cells
during embryogenesis and in the developing central ner-
vous system, sperm cell precursors, female breast ductal
epithelium and B lymphocytes [18]. Consistent with this
expression pattern, male mice lacking A-Myb are infer-
tile because of a block in spermatogenesis, and A-myb
null females have underdeveloped breast tissue after
pregnancy [19]. In marked contrast to the restricted ex-
pression patterns of c-myb and A-myb, B-myb is widely
expressed in cycling cells of all lineages [2, 16, 20–22].
B-myb is expressed early during mouse embryogenesis,
before either c-myb or A-myb, and its expression is re-
stricted to zones of cell proliferation [23]. Consistent
with this, B-myb knock-out mice die at a very early stage
of development (E4.5–E6.5), and a requirement for B-
Myb in inner cell mass formation is indicated by the se-
verely impaired proliferation of these pluripotent cells
when blastocysts were explanted and cultured in vitro
[24]. 
The fact that B-myb expression is strongly associated
with proliferating cells of all lineages suggests that this
gene may play an important and general role during the
cell cycle. This notion is supported by studies showing
that B-myb antisense oligonucleotides inhibit prolifera-
tion of myeloid, lymphoid, glioblastoma, fibroblast and
neuroblastoma cell lines [25–28], while constitutive B-
myb expression allows BALB/c 3T3 fibroblasts to grow
in low serum conditions [26] and prevents cell cycle ar-
rest in interleukin (IL)-6-induced differentiation of M1
myeloid leukaemia cells [29]. The purpose of this review
is to discuss recent developments in our knowledge of B-
myb regulation during the cell cycle and to suggest what
part B-Myb may have in regulating cell proliferation. 
Cell cyle regulation of B-myb transcription
The fact that B-myb transcription is very tightly regulated
during the cell cycle provides a key piece of evidence that
the B-Myb protein provides a function required in prolif-
erating cells. Thus, early studies showed that B-myb
mRNA levels were undetectable by Northern blot in
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murine fibroblasts and human keratinocytes arrested by
serum deprivation [20, 21, 30], and in quiescent human T
and B lymphoid cells [16]. After stimulation of these
cells, B-myb expression was not induced until mid to late
G1, and reached its maximum levels during S phase.
Moreover, in G2/M synchronised NIH 3T3 fibroblasts,
B-myb mRNA levels were found to decrease in G1 before
again peaking at S phase, indicating that B-myb tran-
scription is determined by the cell cycle phase rather than
by the presence of mitogens [21]. 
Run-on transcription studies showed that B-myb mRNA
induction in late G1 is due largely to an increase in gene
transcription [21], suggesting that B-myb may be an E2F
transcription factor-regulated gene. Indeed, the promoters
of both the mouse and human B-myb genes contain a per-
fectly conserved E2F-binding site (fig. 2) which we
showed is critical for cell cycle regulation of transcription
[30, 31]. Mutation of the B-myb promoter E2F-binding
site resulted in constitutively high levels of expression
throughout the cell cycle, a finding which ran counter to
the prevailing view of the time that E2F is an activator of
transcription. Co-expression of the 12S adenovirus E1A
or human papillomavirus type 16 E7 genes enhanced the
activity of the wild-type B-myb reporter activity, but not
that of a B-myb promoter carrying a mutated E2F site.
Since E1A and E7 target the Rb family of pocket proteins
and disrupt their binding to E2F, the B-myb promotor was
postulated to be regulated by transcriptional repression
involving E2F complexes bound to members of the Rb
family [31, 32]. Activation of transcription in late G1
would then utilise constitutively bound transactivators,
such as Sp1, which recognise sites upstream of the E2F
site, and whose activity is presumably suppressed in
Figure 1. The B-Myb protein. Schematic representation of the B-Myb protein showing the described domains: the N-terminal DNA-bind-
ing domain is composed of three subdomains R1, R2 and R3. The overall amino acid identity of this region among Myb proteins is 75%.
Also shown are the adjacent acidic region, the conserved region (CR, which has an amino acid identity of 45% among Myb proteins) and
the negative regulatory domain (NRD). The serine and threonine residues phosphorylated by the action of cyclin/cdk2 kinases are shown
(amino acid residues shown relate to mouse B-Myb). The four conserved lysine residues which are putatively acetylated by CBP/p300 are
also indicated.
G0/early G1 by E2F/pocket protein complexes. In this
simple model, activation of transcription therefore re-
flects derepression of the promoter (fig. 2). 
The precise mechanism operating on transcriptional reg-
ulation of B-myb has been the subject of several studies.
Using E7 mutants that discriminate between pocket pro-
teins, we deduced that transcriptional repression de-
pended on p107/E2F rather than Rb/E2F complexes in
NIH3T3 fibroblasts [32]. In other cell types, p130 was
the predominant protein found in E2F complexes binding
to the B-myb promoter during quiescence [30, 33]. Evi-
dence supporting the notion that B-myb promoter repres-
sion requires either p107 or p130 has come from studies
of embryonic fibroblasts derived from gene knock-out
mice [34]. Significantly, B-myb expression was unaf-
fected in mouse embryo fibroblasts (MEFs) derived from
either p107 –/– or p130 –/– knock-out animals; however, in
double-knock-out p107 –/–; p130 –/– MEFs, B-myb tran-
scription was strongly derepressed during G0/early G1.
Other genes such as cdc2, E2F1 and cyclin A2 were also
deregulated in these cells. In contrast, B-myb expression
was unaffected in Rb –/– MEFs, although the cyclin E and
p107 genes were strongly deregulated in these cells. This
study indicates a functional redundancy between p107
and p130 in repression of B-myb transcription during
G0/early G1 that cannot be compensated for by Rb. Con-
sistent with this conclusion, transfection of p107–/–;
p130 –/– MEFs with either p107 or p130 repressed the 
B-myb promoter, whereas pRb had no significant effect
[34, 35]. 
The major question that arises from these findings is how
does the B-myb promoter discriminate between E2F com-
plexes containing p107/p130 and Rb? Certainly, Rb/E2F
complexes are able to bind to the B-myb promoter in in
vitro electrophoretic mobility shift assays (EMSAs) and,
notably, these complexes are very abundant in quiescent
p107–/–;p130–/– MEFs [34, 35]. However, in vivo methy-
lation footprinting showed that the B-myb E2F site was
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Figure 2. B-Myb: a cell cycle-regulated gene. The B-myb gene is precisely regulated along the cell cycle. In quiescent and G0-arrested
cells, the B-myb promoter is highly repressed by a protein complex bound to the E2F site and downstream repression site (DRS). Among
the proteins identified to date which are involved in B-myb repression are E2F4 and its partner DP, the Rb proteins p107 and p130, the hi-
stone deacetylase HDAC1 and the repressor mSinB3. Although the relevance of the DRS site on B-myb gene regulation has been well es-
tablished, the nature of the downstream regulatory factor (DRF) has yet to be characterized. In this phase of the cell cycle, histones are
mainly deacetylated. During mid to late G1, the repressor complex is removed and substituted by other proteins, and E2F1/3-DP complexes
are transiently detected at that stage. The presence of histone acetylases (HATs) has also been described and may be responsible for the hi-
stone acetylation detected in this phase. Since HATs do not directly bind to DNA, they may interact through E2F1/3 (as described for 
CBP) or through additional factors (X) yet to be characterised. At the S phase of the cell cycle, B-myb transcription is fully derepressed 
and the promoter reaches its highest activity. During that phase, the E2F and DRS sites are unoccupied and histone acetylation is at its 
maximum. Transcription may also be driven by the cooperative activity of SP1 and B-Myb itself. The involvement of unknown proteins
bridging Sp1 and B-Myb is also possible.
unprotected in p107–/–;p130–/– MEFs, indicating the ab-
sence of interacting E2F complexes in these cells,
whereas the site was protected in wild-type and Rb –/–
MEFs. Similar footprinting studies showed that this site
is occupied in vivo in G0/early G1 when the B-myb pro-
moter is repressed, but unoccupied at late G1/S when B-
myb is expressed [36]. Notably, the latter study suggests
that activating E2F species (i.e. E2F-1, E2F-2 and E2F-3
unbound to pocket proteins), which are prevalent at late
G1/S, do not bind stably to the B-myb promoter. This con-
clusion is consistent with the notion that B-myb tran-
scription is regulated predominantly by a repression-
derepression mechanism [31]. Overall, these findings
suggest that discrimination between E2F complexes
binding to the B-myb promoter depends upon chromatin
structure rather than the primary DNA sequence. The
most informative studies in this area are therefore those
which look at what is going on in intact cells, and partic-
ularly useful in this respect is the chromatin immunopre-
cipitation (ChIP) assay. 
ChIP assays carried out with NIH 3T3 fibroblasts showed
that E2F-4/p107 and E2F-4/p130 complexes were associ-
ated with the B-myb promoter in G0, while in early G1,
only E2F-4/p107 complexes remained [37]. Free E2F-4
(i.e. devoid of pocket proteins) was detected transiently
on the B-myb promoter at the G1/S transition, although
no other E2F species were seen at this stage, while in S
phase, no E2F or pocket proteins could be detected at all.
This latter situation is unique to B-myb, since all other
E2F-regulated promoters analysed bind E2F species dur-
ing S phase [37]. Another study using the human T98G
glioblastoma cell line also found that the B-myb promoter
is uniquely free of associated E2F and pocket proteins
during S phase [38], although some details of the factors
binding in G1 differed between this cell line and NIH 3T3
cells. The major discrepancy is that E2F-1 and E2F-3, but
not E2F-4, were found to be associated with the B-myb
promoter in T98G cells in late G1. 
Although the predominant E2F complexes binding to the
B-myb promoter are associated with pocket proteins and
are likely to repress transcription, free E2F species were
detected transiently in late G1, implying that they may
have a role in transactivating the promoter. This notion is
consistent with studies carried out in E2F3–/– MEFs,
where the expression of B-myb and other cell cycle regu-
lated genes such as cdc2, cyclin A2 and cdc6 is strongly
impaired when quiescent cells are stimulated to reenter
the cell cycle by addition of serum. In contrast, none of
these genes was found to be deregulated in E2F1–/– MEFs
[39]. This study suggests that E2F-3 has a transient role
in transactivating the B-myb promoter late in G1, at least
in certain cell types. In opposition to this notion, a B-myb
promoter containing a mutated E2F site was found to be
highly active in stably transfected NIH 3T3 cells [40]. Al-
together, this may point to E2F-3 activation operating
through an alternative binding site in B-myb, potentially a
site which is not present in the promoter sequences used
in transfection experiments, and the resolution of this is-
sue requires further study. 
B-myb is a highly repressed gene in quiescent cells, and
recent studies have begun to address how this is achieved.
Core histones on the B-myb promoter are under-acety-
lated in G0/early G1 when transcription is silenced, while
B-myb derepression correlates with an increase in H3 and
H4 acetylation [38]. These findings suggest that p107 and
p130 may recruit histones deactetylases (HDACs) to the
B-myb promoter at G0/early G1 and that histone acety-
lases (HATs) may replace HDACs during the G1/S tran-
sition (fig. 2). Indeed, ChIP analysis carried out on fi-
broblasts detected the presence of HDAC1 and the co-re-
pressor mSin3B on the B-myb promoter during G0 [40].
Notably, the recruitment of HDAC1 and mSin3B was not
observed in p107 –/–;p130–/– MEFs and was completely
abolished in a B-myb transgene harbouring a mutated
E2F site. Therefore, E2F4 complexes containing p107/
p130 may repress B-myb transcription by either recruiting
HDACs and co-repressors or by physically excluding
HATs from the promoter at G0/early G1 (fig. 2). 
As noted above, regulation of B-myb transcription by E2F
has some unconventional features, most notably the
prevalence of repressor complexes and the complete ab-
sence of associated E2F species during S phase. This ec-
centricity suggests unique features of the B-myb E2F site,
or its context. Consistent with this notion, we encoun-
tered a co-repressor site (fig. 2) referred to as the down-
stream repression site (DRS), which is located just a few
nucleotides 3¢ of the E2F site [33]. Mutation of the DRS
resulted in B-myb promoter derepression in G0 in a simi-
lar manner to mutations in the adjacent E2F site. Curi-
ously, mutating the DRS had no effect on E2F binding in
in vitro assays such as EMSA [33]. Recently, however,
ChIP assays carried out on a B-myb transgene harbouring
mutations in the DRS have shown that p130 and p107
binding to the E2F site is compromised in vivo [35]. We
conclude that the DRS acts specifically in vivo to recruit
repressor E2F-4/p107 and E2F-4/p130 complexes to the
adjacent E2F site, potentially by modifying the nucleo-
some conformation or positioning in this region (fig. 2).
The presence of the DRS may therefore explain why re-
pressor E2F complexes predominate on the B-myb pro-
moter. 
Virtually all studies on B-myb transcriptional regulation
have been done with cells arrested in, and released from,
G0, and there is relatively little information on what hap-
pens when cells receive an inhibitory stimulus and arrest
at a cell cycle checkpoint. G1 arrest triggered by p16INK4a,
transforming growth factor-b (TGF-b) and contact inhi-
bition is mediated by E2F-dependent transcriptional 
repression [41], and TGF-b-induced G1 arrest has been
suggested to result from its inhibitory effect on expres-
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sion of B-myb and cyclin A [42]. A recent report by Chen
and collegues has elucidated the cascade of events that
links the activation of the TGF-b receptor with c-myc
transcriptional repression [43]. Thus, TGF-b receptor ac-
tivation induces phosphorylation of the Smad3 protein,
some of which exists as a cytosolic complex with E2F3/4-
DP1 and p107. Phosphorylated Smad3 is able to recruit
Smad4 and translocate the multicomplex to the cell 
nucleus, where it represses TGF-b-responsive genes like
c-myc. Clearly, it is of interest to determine whether a
similar mechanism acts on B-myb transcription. 
Cell cycle-regulated phosphorylation of B-Myb
Reflecting the strict transcriptional regulation of the B-
myb gene during the cell cycle, B-Myb protein levels are
low in G0-arrested cells, but are induced in late G1 fol-
lowing serum stimulation and peak at the onset of S phase
[44]. Interestingly, induction of expression in late G1/S is
accompanied by the appearance of a more slowly migrat-
ing B-Myb form that runs at an apparent molecular
weight of 112 kDa. Treatment of cell extracts with phos-
phatases reduced the apparent molecular weight of B-
Myb to 110 kDa [12, 44], similar to that seen in G0/early
G1. These reports were the first to show that B-Myb was
modified by phosphorylation during S phase. The timing
of this modification correlated with cyclin E and cyclin
A-cdk2 activation [45], and these cyclin/cdk complexes
are the most likely candidates to phosphorylate B-Myb.
Indeed, using baculovirus-expressed proteins, B-Myb
was shown to be preferentially a substrate for cyclin
A/cdk2 activity [44], while cyclin E/cdk2 and cyclin
D1/cdk4 had little effect. Moreover, cyclin A was able to
induce a B-Myb mobility shift in transfected COS-7 and
U-2 OS cells [12, 46], while both cyclin A and cyclin E
were able to do so in Saos 2 cells [47]. Importantly, co-
transfection of cyclin A/cdk2 with B-Myb was found to
result in a substantial enhancement of transactivation
function [8, 11, 12, 47], suggesting that the transcrip-
tional properties of B-Myb are positively regulated by cy-
clin/cdk-mediated phosphorylation at late G1/S phase. 
Further evidence that cyclin A/cdk2 is primarily respon-
sible for B-Myb phosphorylation in S phase has come
from two-dimensional tryptic peptide mapping. This
showed that cyclin A/cdk2 phosphorylated similar B-
Myb sites both in vitro and in vivo; furthermore, the spot
pattern was very similar to that obtained from S phase-
synchronised Swiss 3T3 fibroblasts [12]. The use of this
methodology in combination with point mutagenesis of
putative cdk phosphorylation sites (Ser/Thr-Pro) allow-
ed the indentification of Thr443/447/490/497/524 and
Ser581 as in vitro and in vivo cyclin A/cdk2 substrates
[46, 48, 49]. Notably, B-Myb transcriptional activity was
reduced between 40–50% with respect to wild type B-
Myb in the single point mutants T447A, T524A and
S581A, while a mutant harbouring four mutated sites
(T447A, T490A, T497A and S581A) was barely activated
by ectopic cyclin A [46, 48]. Thus, the co-ordinated phos-
phorylations of different Thr and Ser residues in the 
B-Myb C terminus synergise to increase B-Myb tran-
scriptional activity. More recently, the use of automated
phosphopeptide radiosequencing has allowed the iden-
tificaction of several more cyclin E/A-cdk2 phosphory-
lation sites in B-Myb (fig. 1), and a mutant carry-
ing substitutions in all 15 reported B-Myb phosphory-
lation sites is unable to transactivate the FGF4 promoter
and behaves as a dominant negative, presumably by 
competing with wild-type B-Myb for binding to MBSs
[50, 51]. 
The B-Myb C-terminus (fig. 1) contains an NRD, and its
deletion generates proteins with high transcriptional ac-
tivity that cannot be further activated by phosphorylation
[8, 11, 12, 52]. The role of phosphorylation has therefore
been postulated to overcome negative regulation con-
ferred by the NRD, and a number of studies have investi-
gated how this mechanism may operate at the protein in-
teraction level. One possible mechanism was suggested
by the observation that one of the phosphorylation sites
(S581) lies within a nuclear localisation domain. How-
ever, mutation of this site had no effect on intracellular lo-
calisation of B-Myb; moreover, the B-Myb protein re-
mains in the cell nucleus throughout the cell cycle sug-
gesting that phosphorylation has no effect on this
property [44]. A further mechanism was suggested by the
observation that C-terminally truncated B-Myb has an in-
creased affinity for DNA [52]. However, binding of full-
length B-Myb to either a single or a concatenated MBS
was not increased upon cyclin A-mediated phosporyla-
tion. Currently, the most favoured models for B-Myb ac-
tivation by phosphorylation are either that this increases
the affinity of B-Myb for a co-activating protein or, alter-
natively, reduces its affinity for a repressor protein. 
B-Myb co-activators
In common with other Myb proteins, B-Myb has been
found to interact both functionally and physically with
the transcriptional co-activators, CREB-binding protein
(CBP) and the related p300 protein [51–53]. Both these
co-activators respond to multiple signalling events by act-
ing as scaffolding proteins that connect sequence-spe-
cific transcription factors to the basal transcriptional ma-
chinery. Additionally, p300 and CBP have intrinsic HAT
activity, and therefore may be involved in chromatin re-
modelling through acetylation of nucleosomal histones as
well as by modifying interacting transcription factors
such as B-Myb [reviewed in ref. 54]. The ability of CBP
to synergise with B-Myb transcriptional activity was
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found to be strictly dependent on cyclin A-mediated
phosphorylation of B-Myb [52]. Surprisingly, in view of
this finding, evidence obtained to date indicates that the
phosphorylation status of B-Myb does not affect binding
to either CBP or p300 [51, 52]. Explaining these some-
what discordant findings is uncertain at present, but a
simple model in which CBP/p300 activates the transacti-
vation function of B-Myb by specifically recognising
phosphorylated domains is clearly a non-starter. Pertinent
is that CBP/p300 acetylates five lysine residues in the
NRD of the mouse c-Myb protein and their substitution
to arginine strongly impairs c-Myb transcriptional activ-
ity [55, 56]. Since four of these lysine residues are con-
served in B-Myb, one may reasonably argue that lysine
acetylation is an important post-translational modifica-
tion with huge implications for Myb function. One possi-
ble explanation of the results, therefore, is that cyclin A-
mediated phosphorylation of key serine and threonine
residues located in the CR/NRD domain of B-Myb may
alter the conformation of this region and allow the asso-
ciated CBP/p300 access to the substrate lysines. The sub-
sequent acetylation of these residues would account for
the synergy between cyclin A and CBP/p300, and would
explain why inhibiting phosphorylation ablates enhance-
ment of B-Myb transcriptional activity. Further work in
this area is required to resolve these issues. 
The poly(ADP-ribose) polymerase (PARP) protein has
also been reported to be a co-activator of B-Myb [57].
This activity is dependent upon a physical interaction be-
tween these proteins which involves the B-Myb DNA-
binding domain, but is not dependent upon the poly-ADP
ribosylation activity of PARP. Notably, PARP and cyclin
A synergise to drive B-Myb transcriptional activity [58],
while a B-Myb mutant containing substitutions in ten cy-
clin A/cdk2 phosphorylation sites [50] failed to be co-ac-
tivated by PARP expression. Although these data initially
suggested that PARP interacts specifically with phospho-
rylated B-Myb, further evidence indicated that in fact
PARP facilitates phosphorylation of B-Myb. Indeed, cy-
clin A was found to be unable to enhance B-Myb activity
in PARP–/– fibroblasts, suggesting that PARP might in-
duce a conformational change in B-Myb that would ex-
pose C-terminal phosphorylation sites to cyclin A/cdk2
[58]. These data suggest that synergy between B-Myb
and CBP/p300 could also be accounted for by a similar
mechanism, as indeed we have previously proposed [52].
The interactions made by B-Myb with co-activators are
summarized in figure 3.
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Figure 3. The B-Myb cycle: from birth to death. The B-Myb protein is highly repressed through its interaction with proteins such as cy-
clin D1 and N-CoR. As cells progress to G1, cyclin D1 is degraded and removed from the complex. Additionally, B-Myb undergoes pro-
tein phosphorylation by the activities of the cyclin/cdk2 kinase complexes. As a consequence, B-Myb is released from the N-CoR complex
and becomes transcriptionally active. That activity may be further increased by the association of B-Myb with the co-activators PARP and
CBP/p300. The latter is also responsible for B-Myb acetylation, which may result in a further increase in gene transcriptional activity. On
the other hand, B-Myb protein binds to the cyclin-binding domains of the RB protein p107. As a result, cyclin/cdk2 kinase complexes are
further activated generating more phosphorylated B-Myb. Phosphorylated B-Myb is recognised by p45Skp2, the F component of the SCF
complex formed by Skp1 and Cul-1, which has E3 ubiquitin ligase activity. Ubiquitinated B-Myb is rapidly targeted for degradation by the
26S proteasome.
B-Myb repressors
The transcriptional activity of B-Myb is repressed
through interactions with the co-repressor proteins N-
CoR/SMRT [53, 59] and BS69 [59]. The closely related
N-CoR and SMRT proteins are components of multipro-
tein complexes containing HDACs, which bind and re-
press many other transcription factors [60]. The B-Myb C
terminus has recently been shown to interact with the nu-
clear receptor-binding domain of N-CoR, and transcrip-
tional repression of B-Myb can be overcome by co-ex-
pressing the unliganded thyroid hormone nuclear recep-
tor. Repression of B-Myb activity can also be overcome
with the HDAC inhibitor trichostatin A (TSA), which
suggests that recruitment of HDACs to an N-CoR/B-Myb
or SMRT/B-Myb complex may account for the inhibitory
effect. Significantly, the association with N-CoR was re-
duced when B-Myb was modified by cyclin A/cdk2 [53].
Furthermore, N-CoR is unable to bind to transcriptionally
activated mutants of B-Myb which lack the NRD. These
findings suggest a model in which N-CoR/SMRT bind-
ing to B-Myb is disrupted by cyclin A/cdk2 phosphoryla-
tion (fig. 3). This would enable the acetylase activity pro-
vided by B-Myb-associated CBP/p300, now unfettered
by HDAC activity associated with N-CoR/SMRT, to
modify histones and other regulatory proteins (possibly
including B-Myb itself) and stimulate transcription. C-
terminally truncated B-Myb lacking the NRD would not
require phosphorylation for this activity, as it does not
bind N-CoR/SMRT. Although this is an interesting
model, further work is required to prove its validity. In-
deed, other researchers find that C-terminally truncated
B-Myb binds N-CoR as efficiently as wild-type B-Myb
[59], and suggest that physical interactions with the BS69
protein, which was first identified as a protein that binds
and inhibits the adenovirus 5 E1A oncogene [61], con-
tributes to the transcriptional repression activity of 
B-Myb. 
Role of ubiquitination in regulating B-Myb activity
Another means to control protein activity is at the level of
protein stability, and many regulators of the cell cycle and
transcription are in fact short-lived proteins regulated by
protein degradation through the ubiquitin-proteasome
pathway [62, 63]. B-Myb protein levels were initially ob-
served to be substantially reduced when cyclin A was co-
expressed [46], suggesting that phosphorylated B-Myb
may be targeted for ubiquitination. Indeed, the B-Myb
protein half-life was found to be reduced from 2.7 h to 50
min after cyclin A expression, while this effect was com-
promised by proteasome inhibitors such as lactacystin
[64]. Moreover, poly-ubiquitination of wild-type B-Myb
was increased in cyclin A-co-transfected cells while it
barely affected the half-life of a C-terminally truncated
protein, namely B-Myb 1–508. Degradation of B-Myb was
accelerated in cells co-transfected with the F-box protein
p45Skp2, which is a cell cycle-regulated component of the
ubiquitin/proteasome pathway maximally expressed dur-
ing S phase [64]. Ubiquitination of cyclin A/cdk2-modi-
fied B-Myb may therefore have a role in limiting the tran-
scriptionally hyperactivated protein to S phase. More
speculatively, proteasomal targeting of phosphorylated
B-Myb may generate transcriptionally activated frag-
ments from which the NRD has been excised. However,
there is no evidence that C-terminally truncated B-Myb
fragments accumulate in cells expressing cyclin A/cdk2
as would be predicted by this model [46]. 
B-Myb cell cycle regulation: transcription factor
activity
The most obvious requirement for B-Myb function in the
cell cycle is as a regulator of gene transcription Indeed,
the experimental use of inducible dominant interfering
Myb proteins, consisting of the DNA-binding domain
linked to a regulatable estrogen receptor/engrailed tran-
scriptional repression module [52, 65], suggests that the
transcriptional activity of B-Myb is required for cell
growth. These interfering proteins were designed to bind
to MBSs present in the transcriptional regulatory se-
quences of target genes, blocking transcription through
the action of the Engrailed repression domain. Mouse
embryonal stem (ES) cells expressing an interfering Myb
protein showed a defect in G1/S transition and an appar-
ently independent reduction in cell adhesion. Although
all three members of the vertebrate Myb family bind the
same consensus MBS, and therefore may regulate the
same gene set, the defects observed are likely due to in-
terference with B-Myb-regulated transcription, since this
is the only member of the family which is expressed in
these primitive progenitor cells. Which target genes are
affected by the interfering Myb mutant remains un-
known.
B-Myb notably binds the MBS less avidly than either c-
Myb or A-Myb and has less tolerance of binding site vari-
ations [66]. This suggests that B-Myb is a weaker tran-
scriptional activator which could be supplanted by the
other Myb family proteins in cells where they are co-ex-
pressed. However, studies to date indicate that B-Myb
gene transactivation is not straightforward, being in some
instances independent of DNA binding and, as discussed
above, clearly affected by post-translational modifica-
tions and by the presence of co-repressors and co-activa-
tors. As discussed in detail below, a number of potential
B-Myb target genes have now been proposed, and B-Myb
has evidently evolved several strategies to regulate tran-
scription. 
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MBS-independent promoter regulation is best exempli-
fied by the human HSP70 gene. Expression of HSP70
peaks during S phase [67], and it is notable that this coin-
cides with maximal levels of B-Myb [21, 30]. Transacti-
vation of the HSP70 promoter is abrogated by removal of
the TATA box, suggesting that in this case B-Myb may
regulate gene transcription through direct or indirect in-
teractions with components of the basal transcriptional
machinery [68]. Recently, B-Myb was suggested to be
titrating out the transcriptional co-repressor N-CoR and
releasing the nuclear hormone receptor TRb, which
would then directly transactivate the HSP70 promoter
[53]. 
A number of other promoters which lack MBSs have also
been reported to be transactivated by B-Myb, for exam-
ple, DNA polymerase alpha [69], B-myb itself [70] and
the fibroblast growth factor 4 (FGF4) promoter [51]. Al-
though some caution is advisable in the interpretation of
these results – in particular, evidence is lacking that these
genes are bona fide in vivo targets for B-Myb – the abil-
ity of B-Myb to act as a promiscuous, albeit rather weak,
transactivator must reflect some significant property of
the protein. In this respect, of interest is that B-Myb acts
through a GC-rich region containing several putative
Sp1-binding sites for transactivation of its own promoter
[70]. Indeed, Sp1 was found to synergize with B-Myb to
transactivate the B-myb promoter [70]; moreover, these
proteins are able to interact in vivo. Association with Sp1
may therefore allow B-Myb to be recruited to promoters
containing Sp1-binding sites (fig. 2). As these binding
sites are common promoter components, this mechanism
would potentially allow B-Myb recruitment to numerous
genes. 
B-Myb has been reported to transactivate a number of
promoters through MBS-dependent regulation, although
in general the data relate only to transient co-transfec-
tion/reporter assays. Transactivation of the c-myc proto-
oncogene promoter by B-Myb appears to be mediated
through several MBSs which are present in this sequence
[71], while transactivation of the human DNA topoiso-
merase IIa promoter appears to require a single MBS
[72]. Although both of these genes have important roles
in cell proliferation, there is as yet little evidence that the
promoters of the endogenous genes are true targets for B-
Myb in vivo. Similarly, the human cyclin A1 promoter
contains several MBSs close to the mRNA initiation site,
and can be transactivated by B-Myb (and c-Myb) in tran-
sient co-transfection assays [49, 73]. Cyclin A1 is ex-
pressed in proliferating cells during spermatogenesis and
is also transcribed in myeloid leukaemias; B-Myb is co-
expressed in these cells, and may potentially regulate its
expression; however, further evidence is still required to
confirm this. Both c-Myb and B-Myb have recently been
shown to be able to bind to the insulin-like growth factor-
binding protein 5 (IGFBP) promoter in vitro (EMSA as-
says) and in vivo (ChIP assays), and can transactivate the
promoter through an MBS. Notably, neuroblastoma cell
growth is dependent on the supply of growth factors,
which are frequently produced through an autocrine
mechanism, suggesting that Myb proteins may be in-
volved in the regulation of the insulin-like growth factor
axis, and therefore may contribute to the neoplastic trans-
formation of neuroblastoma cells [74].
Several studies suggest that B-Myb regulates genes
which promote cell survival. Representational difference
analysis carried out on LAN-5 neuroblastoma cells ec-
topically expressing B-Myb identified the apolipoprotein
J/clusterin (clusterin) gene as a putative B-Myb target.
The clusterin promoter has an MBS whose mutation im-
pairs B-Myb transactivation in transient co-transfection
assays; moreover, the activity of B-Myb on this promoter
is enhanced by cyclin A2 [75]. The clusterin gene encodes
a sulphated glycoprotein which accumulates during
senescence and in cancer cells, and has been found to pro-
tect cells against tumour necrosis factor a- and oxidative
stress-related apoptosis [reviewed in ref. 76]. Addition-
ally, clusterin expression appears to increase resistance of
neuroblastomas to chemotherapeutic drugs, and of inter-
est is that high levels of B-Myb expression in neuroblas-
toma correlates with poor prognosis [77]. B-Myb over-
expression may therefore contribute to tumour progres-
sion in neuroblastomas by enhancing cell survival
through induction of clusterin. Ectopic expression of B-
Myb has also been found to reduce the dependence of
murine T cells on cytokines while increasing their resis-
tance to several apoptotic agents. This effect correlated
with increased expression of the anti-apoptotic Bcl2
gene, and B-Myb and cyclin A were shown to co-operate
to transactivate Bcl2 through a putative MBS found in the
promoter [78]. Finally, B-Myb can transactivate the pro-
moter of the surfactant protein A (SP-A) gene [79],
whose protein functions as part of the innate immunity of
the lung. Although the mitotic index of lung epithelia is
normally low, cdk2 and cyclin A increase after lung in-
jury and may activate B-Myb to induce expression of 
SP-A in these cells. 
Interestingly, Myb proteins may also act as repressors of
gene transcription, although again, this property of B-
Myb has been described only during over-expression in
transfected cells. Thus, c-Myb and B-Myb repress tran-
scription of the human c-erbB2 (HER2) promoter in an
MBS-dependent way, potentially by binding to an MBS
which overlaps with the TATA box and blocking access to
TFIID [80]. HER2 is frequently amplified in breast ade-
nocarcinomas [81], and it would be interesting to know if
Myb proteins can down-regulate HER2 promoter activity
in cancer cells. Moreover, the bFGF-induced decrease in
mRNA levels and transcription of the type I collagen a1
and a2 genes in bovine aortic smooth muscle cells
(SMCs) is paralleled with induction of B-myb mRNA lev-
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els [82, 83], and co-transfection experiments showed that
B-Myb strongly repressed transcription from the promot-
ers of these collagen genes. The repression mechanism is
not yet known, but both promoters contain putative MBSs
and B-Myb may prevent c-Myb from activating tran-
scription through this site, as has been proposed for the
human type I collagen a2 promoter [84]. However, B-
Myb appears to bind MBSs more weakly than does c-
Myb and, arguably, B-Myb would be a better competitor
at the protein-protein interaction level rather than as a
DNA-binding competitor. Indeed, transcriptional down-
regulation by B-Myb of the type V collagen a2 gene in
aortic SMCs occurs through a promoter region which
lacks MBSs, and this has been suggested to occur via in-
teraction with a positively acting matrix regulatory factor,
termed MRF-V [85]. Taken together, these findings show
the relevance of Myb proteins as key regulators of colla-
gen gene expression.
B-Myb cell cycle regulation: interactions with 
regulatory proteins
B-Myb has been reported to bind to several cell cycle reg-
ulatory proteins, including cyclin D1 [86], cyclin A1 [49]
and p107 [87], suggesting that these interactions may
contribute to the role of B-Myb in cell growth. In this re-
spect, of great interest is that a dual role as transcriptional
activator and component of a DNA replication complex
has been proposed for the Drosophila Myb protein [88],
which appears to be more closely related to B-Myb than
to either c-Myb or A-Myb [89]. Moreover, some studies
indicate that the ability of B-Myb to overcome inhibitory
effects on the cell cycle does not depend upon its tran-
scriptional activity. Thus, ectopically expressed B-Myb
was found to bypass a proliferation block induced by
p53/p21Cip1 in a human glioblastoma cell line [27], and
this activity could also be conferred by a transcriptionally
defective B-Myb mutant. We have been unable to demon-
strate binding in vivo between B-Myb and either p53 or
p21Cip1 [unpublished results], and the molecular mech-
anism behind this observation remains to be elucidated.
Moreover, we have demonstrated that the ability of B-
Myb to overcome a G1 cell cycle block imposed by p107,
a member of the retinoblastoma pocket protein family
[90], is also independent of the transcriptional activity of
B-Myb [91]. In Saos-2 cells, p107 causes G1 arrest
through two mechanisms specified by distinct protein
domains: the action of the large pocket domain that binds
E2F and an extensive N-terminal domain that binds and
inhibits cyclin/cdk2 complexes [92, 93]. We found that B-
Myb binds to the p107 N terminus (between amino acids
10–486) in a domain that overlaps a cyclin A/E-binding
motif [91], suggesting that the critical function that B-
Myb bypasses is inhibition of cyclin/cdk2 activity. In sup-
port of this notion, we could demonstrate that p107-me-
diated inhibition of cyclin E/cdk2 is overcome by B-Myb
expression in co-transfected Saos-2 cells. Significantly,
the B-myb and p107 genes are both under E2F transcrip-
tional control, and their expression is co-ordinately in-
duced in late G1. One function of B-Myb therefore may
be to counteract inhibition of cyclin/cdk2 activity by de
novo synthesised p107 at the critical G1/S boundary (fig.
3). The requirement for this interaction may be cell type
dependent and, of course, would be influenced by the rel-
ative abundance of B-Myb and p107. B-Myb is highly ex-
pressed in ES cells, whose growth appears to depend crit-
ically upon B-Myb [24], and the majority of p107 in these
cells can be depleted by immunoprecipitating with a 
B-Myb antibody [unpublished results]. 
The domains of B-Myb required for p107 binding are
quite ill-defined – deletions within the extreme C-termi-
nal NRD as well as the acidic region both ablate binding
[91] – suggesting that the interaction interface is confor-
mational rather than linear. The involvement of the NRD
raises the possibility that p107 binding may repress B-
Myb transcriptional activity through this domain. Clearly,
however, B-Myb also makes interactions with other pro-
teins through C-terminal sequences, including N-CoR,
and function of the NRD is unlikely to be ascribable to as-
sociation with a unique co-repressor protein. 
Interactions with cyclin D1 and cdk9 do not appear to re-
sult in phosphorylation of B-Myb, and in neither instance
does binding depend upon enzymatic activity associated
with these proteins [86, 94]. Rather, direct interactions
with either cyclin D1 or cdk9 inhibit B-Myb transcrip-
tional activity, indicating that these proteins are negative
regulators (fig. 3). The association between endogenous
B-Myb and cyclin D1 takes place in cells enriched at the
G1/S boundary [86]. Since B-Myb function seems to be
crucial during the G1/S transition, cyclin D1 may hold B-
Myb in a transcriptionally inactive complex in G1 until
such time in late G1/S when cyclin D1 is proteolytically
degraded or B-Myb is activated by cyclin A/cdk2. In sup-
port of this hypothesis, B-Myb transcriptional activity
has recently been reported to be enhanced during the
early stages of neural differentiation, and this coincided
with reduced association with cyclin D1 [95]. In contrast
to cyclin D1, cdk9 levels are not cell cycle regulated and
the physiological relevance of the interaction with B-Myb
is not yet obvious. 
The expression of the cyclin A1 gene is restricted to a very
few tissues; namely, testis, haematopoietic precursors and
several myeloid leukaemic cell lines [96, 97]. Cyclin A1
interacts with the B-Myb C terminus in vitro and these
proteins appear to be associated in vivo in leukaemic
cells. In contrast to cyclin D1 and cdk9, cyclin A1/cdk2
induces B-Myb activity by phosphorylating key threo-
nine and serine residues [49]. Notably, despite the great
similarity between cyclin A1 and cyclin A2, no associa-
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tion between B-Myb and cyclin A2 has been detected in
leukaemic cells [49], mouse embryonic stem cells or in
transfection experiments [unpublished results] suggesting
that the B-Myb-cyclin A1 association is highly specific.
Since B-Myb is co-expressed in both male germ cells [98]
and haematopoietic cells [16], it would be interesting to
know its relationship with cyclin A1 in these cells.
Perspectives
The B-myb gene is subject to two levels of control during
the cell cycle: at the transcriptional level through the ac-
tion of the E2F and Rb family of proteins and at the post-
translational level through the action of late G1/S phase-
specific kinases, in particular cyclin A/cdk2. The first
mechanism ensures that B-myb is transcribed only in pro-
liferating cells, and directs maximal synthesis of B-Myb
protein to late G1/S in cycling cells. The second mecha-
nism ensures that the transcriptional activity of B-Myb in
cycling cells, where B-Myb protein is present throughout
the cell cycle (albeit at fluctuating levels), is enhanced
specifically in late G1/S. The existence of these coupled
regulatory modes points to the inescapable conclusion
that B-Myb plays a significant role in the cell cycle dur-
ing late G1/S. At present, however, we are only scratching
the surface in our understanding of the precise nature of
this role.
Experimental evidence points to a two-fold role for B-
Myb in the cell cycle: (i) by acting as a transcription fac-
tor to regulate expression of genes required for cell cy-
cling and (ii) by making direct interactions with cell cy-
cle regulators such as p107 and p57 Kip2. Significantly, the
related Drosophila Myb protein has been shown to func-
tion both in transcriptional regulation and more directly
as part of a DNA replication complex, and these studies
in the fly may help us understand what B-Myb does in the
mammalian cell cycle. Notable in this respect is that
Drosophila Myb mutants display defects in progression
through both S and M phases of the cell cycle and accu-
mulate chromosomal abnormalities [99–101]. Con-
versely, over-expressing Drosophila Myb induces cell cy-
cle progression through S and M phases and suppresses
endoreduplication [102]. Although the precise effects
seen in these experiments depended on the cell type
analysed, the fly protein is clearly intimately involved in
the cell cycle. Effects on G2/M progression have been as-
cribed to the involvement of Drosophila Myb in tran-
scription of the cyclin B gene [103], while effects on
G1/S progression may depend upon the induction of other
Myb targets or may result from its direct role in DNA
replication [88, 101]. 
In common with the Drosophila homologue, over-ex-
pression of B-myb has been shown to promote progres-
sion of certain cells into S phase [11, 104], in particular
when it is co-expressed with cyclin A. Unclear at present
is whether this results from the induction of target gene
transcription, direct effects upon cell cycle regulators or
indeed their combination. Our experiments in Saos-2
cells indicate that the ability to interact with p107 is re-
quired for this activity, as transcriptionally hyperactive B-
Myb mutants which had lost the p107-binding function
were unable to co-operate with cyclin A to promote S
phase [unpublished results]. Overall, our experiments in-
dicate that one of the major B-Myb functions contribut-
ing to G1/S progression is maintenance of sufficient lev-
els of cyclin E/cdk2 and possibly cyclin A/cdk2 activity
[91]. Notably, both these kinases play vital roles in pro-
gression into and progress through S phase. 
Gene knock-out studies have shown decisively that B-
Myb plays a critical role in early embryogenesis [24]. The
embryonal defect is so early, however, that sufficient
quantities of cells cannot be obtained from the mutant
embryos to allow biochemical analyses of the defect.
Conditional gene knock-outs based on the Cre/loxP sys-
tem are under development, and there is now the potential
to ablate B-myb expression in cell cultures using RNA in-
terference. These developing technologies should enable
rapid progress in understanding the role of B-Myb in the
cell cycle. 
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